Abera Bioscience AB (NGM:ABERA)

Market Cap	138.57M +42.4%
Revenue (ttm)	11.89M -18.7%
Net Income	-10.45M
EPS	-0.63
Shares Out	20.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,617
Average Volume	25,140
Open	6.60
Previous Close	6.58
Day's Range	6.60 - 6.76
52-Week Range	4.52 - 9.70
Beta	0.69
RSI	59.22
Earnings Date	May 11, 2026

About Abera Bioscience AB

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 5
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: ABERA

Financial Performance

In 2025, Abera Bioscience AB's revenue was 11.89 million, a decrease of -18.74% compared to the previous year's 14.63 million. Losses were -10.45 million, 850.3% more than in 2024.